Keywords: USA, FDA, Novartis, Exjade, Roche, Biogen, Rituxan, Leukemia, CLL

US FDA warns on renal, hepatic and gastro problems with Novartis’ Exjade; clears Roche/Biogen’s Rituxan for CLL

Article | 19 February 2010

In a web site posting yesterday, the US Food and Drug Administration notified health care professionals about recent changes in the Prescribing Information (PI) for Swiss drug major Novartis' Exjade (deferasirox), indicated for the treatment of chronic iron overload due to blood transfusions in patients two years of age and older. New language was added to the Contraindications, Warnings and Precautions and Drug Interactions sections of the PI, including a Boxed Warning, that the product may cause:

• Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in